UnitedHealth Group Inc (UNH) Stock Analysis

Verdict: BUY

Sequential guidance hikes and Optum margin recovery signal an operational turnaround, outweighing Medicare Advantage membership headwinds.

Investment score: 70/100

Analysis as of

Is UnitedHealth Group Inc stock worth reviewing? AI model thesis

The model sees UNH successfully executing a margin recovery in 2026 through pricing adjustments and Optum efficiency, offering attractive risk-adjusted upside toward the consensus target of $471.33.

7-factor investment score

UnitedHealth Group Inc opportunities and risks

What speaks for UNH

What speaks against UNH

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
UNH22.9x0.8x14.6x22.8%3.5%6.3%
ELV19.0x0.5x13.4x39.0%2.5%6.8%
HUM38.8x0.3x18.4x13.7%0.9%-0.9%
CNCn/a0.2xn/a16.1%-2.6%26.2%
MOH1296.0x0.2x26.4x8.0%-0.0%2.5%
HQY32.9x5.6x16.8x75.2%17.4%6.2%
Peer median32.9x0.3x16.8x16.1%0.9%6.2%

Frequently asked questions about UnitedHealth Group Inc (UNH)

Is UNH stock a good investment?

The cached TradeMates AI model rates UnitedHealth Group Inc as BUY with an investment score of 70/100. The model sees UNH successfully executing a margin recovery in 2026 through pricing adjustments and Optum efficiency, offering attractive risk-adjusted upside toward the consensus target of $471.33. This is algorithmic model output, not personal investment advice.

Is UNH stock a buy?

The TradeMates model verdict for UNH is BUY with an investment score of 70/100. Treat this as a model signal to review, not a personal buy recommendation.